Skip to main content
To the Editor: In the meta-analysis by Fusar-Poli et al. (1) appearing in the March 2012 issue, the authors contend that an overall 14% greater striatal dopamine transporter binding in the brains of adults with ADHD was caused by previous exposure to stimulant medications. Based on significant errors in the assignment of treatment status, this conclusion is unsupportable. In their Table 1, the ADHD treatment status of the studies defines “drug-free” as all subjects (100%) having previous exposure, and Figure 4 illustrates a metaregression analysis based on this critical variable—previous treatment status—as derived from the primary source manuscripts.
There are some contradictions with the primary source materials. Two of the studies that were identified as drug free (i.e., from previous medication exposure) in Figure 4 were drug naive. The subjects in the la Fougère et al. study (2) were designated as “drug free” in Table 1, but ADHD subjects were drug naive. The second study is not explicitly identified in Figure 4 but can be inferred because 1) Figure 4 shows three studies in which all ADHD subjects had previous exposure, yet Table 1 lists only two studies in this category, and 2) Figure 4 shows four studies as drug naive, yet Table 1 lists five studies with drug-naive subjects. Table 1 lists the Dougherty et al. study (3) as 100% previous exposure when, as indicated in a clarification published in Lancet (4), there was 67% exposure. The Volkow et al. study (5) is listed and analyzed as if subjects were drug naive, but an earlier version of this Volkow et al. study (6) stated, “Subjects were excluded if they had a prior history of more than 1 month of medication treatment for ADHD.” The Jucaite et al. study (7) appears to fit the Figure 4 regression, as the three subjects with previous drug exposure appear to account for elevated mean dopamine transporter binding of ADHD subjects. Yet, the opposite conclusion can be drawn from the primary source manuscript, in which Figure 3 shows that ADHD subjects with previous medication exposure had lower average dopamine transporter binding (estimated 8 units) than drug-naive ADHD subjects (estimated 10 units). Thus, the Jucaite et al. data support the view that previous stimulant treatment is not associated with increased dopamine transporter binding but overall lower dopamine transporter binding.
If two of the inaccurately designated studies are shifted from the drug-free (100% previous treatment) to drug-naive category, the analysis, the slope of Figure 4, and the conclusions of the paper will change.
Finally, we noticed that Figure 1 shows typical positron emission tomography or single photon emission computed tomography probes for the dopamine transporter. It includes one probe (2β-carbomethoxy-3β-[4-fluorophenyl] tropane [CFT]) not used in the studies in this meta-analysis and excludes two (altropane and cocaine) that are used in the studies in this meta-analysis.

Footnote

Accepted for publication in April 2012.

References

1.
Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U: Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? a meta-analysis. Am J Psychiatry 2012; 169:264–272
2.
la Fougère C, Krause J, Krause KH, Josef Gildehaus F, Hacker M, Koch W, Hahn K, Tatsch K, Dresel S: Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl Med Commun 2006; 27:733–737
3.
Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, Fischman AJ: Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 1999; 354:2132–2133
4.
Baughman FA: Dopamine-transporter density in patients with ADHD. Lancet 2000; 355:1460–1461; author reply 1 461–1462
5.
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM: Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 2009; 302:1084–1091
6.
Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, Logan J, Wong C, Ma Y, Swanson JM, Schulz K, Pradhan K: Brain dopamine transporter levels in treatment and drug-naive adults with ADHD. Neuroimage 2007; 34:1182–1190
7.
Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L: Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005; 57:229–238

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 665
PubMed: 22684601

History

Accepted: April 2012
Published online: 1 June 2012
Published in print: June 2012

Authors

Details

Thomas J. Spencer, M.D.
Bertha K. Madras, Ph.D.
Alan J. Fischman, M.D., Ph.D.
Johanna Krause, M.D.
Christian La Fougère, M.D.

Funding Information

Dr. Spencer has received research support from Cephalon, the Department of Defense, Eli Lilly, Janssen, McNeil Pharmaceutical, NIMH, Novartis Pharmaceuticals, and Shire Laboratories; he has been a speaker for Shire Laboratories and Novartis Pharmaceuticals; he has been an adviser or on an advisory board for Alcobra, Shire Laboratories, and Eli Lilly; he receives research support from royalties and licensing fees on copyrighted ADHD scales through MGH Corporate Sponsored Research and Licensing; and he has a U.S. patent application pending (provisional number 61/233,686) through MGH corporate licensing on a method to prevent stimulant abuse. Dr. Madras is an inventor of and has a patent for [11C]altropane. Altropane has been licensed to Alseres, and Navidea has signed an option agreement to license altropane from Alseres. Dr. Krause receives speaking fees from Janssen, Novartis, Medice, and Shire and has served on the advisory board for Eli Lilly. Dr. Fischman and Dr. la Fougère report no financial relationships with commericial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share